Published September 27, 2021
Technology.org reported on a company founded by Ciprian Ionita that is looking at how artificial intelligence (AI) could improve treatment for certain type of aneurysms.
The goal for QAS.AI is to provide real-time information during a procedure that is based on analysis of previous procedures. The AI derived conclusions can then forecast how likely a selected treatment method is to succeed in the new patient.
“The neurosurgeon is always going to be the driver. Our AI will provide valuable data and predictions to help the surgeon make informed decisions,” says Ciprian Ionita, QAS.AI CEO and a UB assistant professor of biomedical engineering and neurosurgery. The software is based on research done in his lab, and UB has filed a patent application covering the technology.
“The main potential benefit is to reduce the rate of re-treatment,” said Kelsey Sommer, QAS.AI chief operating officer and a doctoral candidate in biomedical engineering. “Re-treament, involving another surgery, can come with so many complications and adds additional treatment costs”
